Home » Our Company

ADC Therapeutics—

Confronting cancer with the full potential of our science

ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).

Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.

Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.

Our Vision

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer

Our Values

Integrity - ethical and authentic in our approach

Creativity - innovate with an entrepreneurial spirit

Accountability - ownership to drive results

Collaboration - partner for better outcomes

Urgency - act decisively and proactively

Our Leadership
and the Board of Directors

MEET THE LEADERSHIP TEAM

MEET THE BOARD OF DIRECTORS

Partnering

At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.

To start the conversation about partnering with ADC Therapeutics, please contact us at [email protected].

Charitable Contributions & Sponsorships

Charitable Contributions
ADC Therapeutics’ interactive portal accepts unsolicited requests for charitable contributions/donations. The Company will evaluate funding requests monthly for events/activities of registered 501(c)3 tax-exempt organizations engaged in a healthcare-related charitable purpose aligned with ADC Therapeutics’ mission and vision. Requests will also be reviewed for consistency with our corporate objectives and compliance policies. Applicants outside of the U.S. must qualify as a charitable organization within the country where they reside.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under this category, we also have portals to evaluate other funding types. See links below:

Sponsorships/Memberships/Non-CME Grants
ADC Therapeutics’ interactive portal accepts unsolicited requests for sponsorships, corporate memberships, and non-CME grants that are aligned with ADCT’s mission, vision, and corporate objectives, and are consistent with our compliance policies.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under one of the mentioned categories, one of our other portals may fit your funding request. See links below:

Our History

2011

June

ADC Therapeutics founded as a spin-off from Spirogen Ltd. which was founded in 2000 and was an early innovator in PBD-based ADC research

2015

June

ADC Therapeutics cofounder Chris Martin appointed CEO

2016

March

First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma

2019

October

First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma

2020

Ron Squarer, former CEO of Array BioPharma, Inc. appointed Chairman of the Board

$267-million IPO with the NYSE ticker “ADCT”

Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl

Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl

Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl

2021

April

CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval

2022

Industry veteran Ameet Mallik joins as CEO

2022

May
Industry veteran Ameet Mallik joins as CEO

2021

April
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl receives FDA approval

2020

November
Biologics license application (BLA) acceptance with
priority review for CD19-targeted, lead investigational
compound loncastuximab tesirine-lpyl
September
Biologics license application (BLA) submission for
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl
June
Announced pivotal phase 2 clinical trial of
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl
May
$267-million IPO with the NYSE ticker “ADCT”
March
Ron Squarer, former CEO of Array BioPharma, Inc.
appointed Chairman of the Board

2019

October
First patient enrolled in phase 2 clinical trial of
investigational compound camidanlumab tesirine,
targeting CD25 in relapsed or refractory Hodgkin
lymphoma

2016

March
First patient enrolled in phase 1 clinical trial of lead
investigational compound loncastuximab tesirine-lpyl,
targeting CD19 in positive B-cell non-Hodgkin lymphoma

2015

June
ADC Therapeutics cofounder Chris Martin appointed CEO

2011

June
ADC Therapeutics founded as a spin-off from Spirogen
Ltd. which was founded in 2000 and was an early
innovator in PBD-based ADC research

ADC, antibody-drug conjugate; PBD, pyrrolobenzodiazepine.

Our Vision

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer

Our Values

Integrity – ethical and authentic in our approach

Creativity – innovate with an entrepreneurial spirit

Accountability – ownership to drive results

Collaboration – partner for better outcomes

Urgency – act decisively and proactively

Being part of ADCT means you are dialed in to a unique and excing professional opportunity. One important way we demonstrate our commitment to you is through our comprehensive benefits programs.

Compensation & Rewards

Competitive salaries – regularly benchmarked
Bonuses – all ADCT employees are eligible for a discretionary bonus
401-K savings plan with a competitive employer match for US-based employees
Contributory pension for European-based employees
Employee Stock Purchase Plan
Annual Equity Grant
Employee Rewards & Recognition

Vacation, Holidays, Sick Leave, Health & Well-Being

We offer a competitive vacation and holiday package
Health Insurance: focusing on your and your family’s health is just as important as your work. ADCT offers a comprehensive beneﬁts package including group Medical, Dental, Vision and Disability coverage plans, Health Spending Accounts, and a variety of voluntary insurance products*
Global Wellness Program – ADCT offers a Global Wellness Education program and Global Employee Assistance beneﬁt to all employees, offering opportunities for employees to learn and practice impactful healthy habits
Hybrid working environment; opportunity to work remotely

Learning & Development

Development opportunities throughout your career at ADCT
Access to our comprehensive Learning Management System, providing opportunities for continuous learning and development

*Some benefits may vary based on the country location, eligibility guidelines, and local regulations.

Laurél Tasso, Executive Assistant

Hear colleagues extol the benefits of working at a small and nimble biotech company

Transcript

I did work for several years at large pharma, the thing about large pharma is you sometimes get lost as an employee number.
We have presence over the US and globally but leadership makes it feel like we’re all together in the same culture , so that I enjoy about this company.
This is a small company, has a small company start-up feel, it’s great to work with so many Innovative people who are good at what they do and are open to new ideas and challenging the status quo
You can work at larger pharmas where you blend in and not heard, you come to ADCT and if you’re motivated if you’re engaged you can really make a meaningful impact.
Working at a small biotech is certainly different than working at a large pharma organization I think some of the things I appreciate are the nimbleness.
At the end of the day that nimbleness and how we can react very quickly is a great thing for patients.
Really the camaraderie you get with your colleagues when working here, we all wear many hats, so it’s really exciting from a developmental prespective as well, not doing one thing and same thing every day, get to do lots of different things get experiences and exposure you
wouldn’t get at a larger company, but at same time we have the support systems that we need to get our job done, so it’s really like the best of both worlds.

Ana Varela, NJ Office Manager

Ana works tirelessly to help patients, even while battling breast cancer herself

Transcript

In 2019 I was diagnosed with stage 4 breast cancer, as anyone who’s been through these types diagnoses I know how devastating it is and how crushing it can be.
So being able to get on a targeted therapy like that does similar work that our drug would do brought a lot of hope into my life and I’m very grateful for that.
So this mission here is just personal I’m excited to bring hope to patients and their families.

Chief Business & Strategy Officer, David Gilman

Hear how David Gilman’s personal journey inspired him to join ADC Therapeutics

Transcript

I made a choice 25 years ago that vast majority of the work that I did was going to be oncology and cancer research.
I had at the time lost my fiancee to lung cancer at a young age and so you know, the tug at the heart string was pretty strong.
And it seemed like sort of the right sweet spot and company evolution that hopefully I could be helpful and have that sense of connection.
I have a tiny little piece in creating a drug that saves a life, even if it were just one.
That makes all the difference to me.

Leaving ADC Therapeutics
You are now leaving ADC Therapeutics’ site. ADC Therapeutics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave ADCTherapeutics.com?

LEAVE ADCTHERAPEUTICS.COMLEAVE ADCTHERAPEUTICS.COM

ADC Therapeutics—

Confronting cancer with the full potential of our science

Our Vision

Our Values

Our Leadership
and the Board of Directors

Partnering

Charitable Contributions & Sponsorships

Our History